Companies with non-deal roadshows or company visits/marketing with sell-side today: Crispr Therapeutics (NASDAQ:CRSP) JMP NDR New York For a daily calendar of NDRs, conferences,...
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ:CRSP) on Tuesday, setting a price target of $171, which is approximately 100.99%...
Currently, only about a third of all 3,000 US-listed ETFs are actively managed funds. However, data from 2021 shows that those numbers have been growing dramatically; approximately...
Many on Wall Street are keen to invest in cutting edge, emerging technologies such as Artificial Intelligence (AI), which “enables computers and machines to mimic the...
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.
|Average||115.30 (+86.09% Upside)|
|No. of Analysts||27|